David M. Polen
Polen Capital Management
Polen Capital Management Thermo Fisher Scientific Inc stake
total: 588
Polen Capital Management TMO trades
- Total transactions:
- 14
- New positions:
- 1
- Sold out:
- 1
- Added:
- 2
- Reduced:
- 10
- Held since:
- 2022 Q4
- Held for:
- 13 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q2 report, Polen Capital Management doesn't hold any Thermo Fisher Scientific Inc (TMO) shares. To date, the estimated cost basis is nearly $561.96 for "buy" trades and estimated average "sell" price is $505.83. Polen Capital Management first purchased TMO in 2022 Q4, initially acquiring about 2.19M shares. Since the initial investment in Thermo Fisher Scientific Inc (TMO), Polen Capital Management has made 13 more transactions.
When did Polen Capital Management sell Thermo Fisher Scientific Inc (TMO)?
Polen Capital Management sold off the entire Thermo Fisher Scientific Inc (TMO) position in 2026 Q1.
When did Polen Capital Management buy Thermo Fisher Scientific Inc (TMO)?
Polen Capital Management first invested in Thermo Fisher Scientific Inc (TMO) in 2022 Q4 at the reported quarter-end price of $550.69 per share.
What's the cost basis of Polen Capital Management's TMO stake?
The estimated cost basis for Thermo Fisher Scientific Inc (TMO) stake is around $561.96 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $561.96
- Weighted AVG sell price:
- $505.83
Polen Capital Management's historical trades in Thermo Fisher Scientific Inc
14 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.00%
|
0
|
$579.50
|
|
-100% (-2,307)
|
-0.01%
|
|
2025 Q4
|
0.01%
|
2,307
|
$579.50
|
$1,336,900
|
-97.99% (-112,206)
|
-0.21%
|
|
2025 Q3
|
0.18%
|
114,513
|
$485.02
|
$55,541,018
|
-94.77% (-2,075,835)
|
-3.09%
|
|
2025 Q2
|
2.73%
|
2,190,348
|
$405.46
|
$888,098,672
|
-5.69% (-132,134)
|
-0.17%
|
|
2025 Q1
|
3.63%
|
2,322,482
|
$497.60
|
$1,155,666,992
|
-5.64% (-138,713)
|
-0.19%
|
|
2024 Q4
|
3.46%
|
2,461,195
|
$520.23
|
$1,280,387,702
|
-12.31% (-345,591)
|
-0.46%
|
|
2024 Q3
|
4.48%
|
2,806,786
|
$618.57
|
$1,736,193,727
|
-9.52% (-295,224)
|
-0.46%
|
|
2024 Q2
|
4.30%
|
3,102,010
|
$553.00
|
$1,715,411,476
|
-4.81% (-156,917)
|
-0.2%
|
|
2024 Q1
|
4.37%
|
3,258,927
|
$581.21
|
$1,894,120,742
|
+60.29% (+1,225,807)
|
+1.64%
|
|
2023 Q4
|
2.60%
|
2,033,120
|
$530.83
|
$1,079,249,790
|
-5.48% (-117,908)
|
-0.16%
|
|
2023 Q3
|
2.86%
|
$506.17
|
-3.91% (-87,621)
|
|||
|
2023 Q2
|
2.90%
|
$521.75
|
-1.42% (-32,287)
|
|||
|
2023 Q1
|
3.45%
|
$576.37
|
+3.52% (+77,225)
|
|||
|
2022 Q4
|
3.52%
|
$550.69
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.